Literature DB >> 12147151

Adherence to oral hypoglycaemic agents prior to insulin therapy in Type 2 diabetes.

J M M Evans1, P T Donnan, A D Morris.   

Abstract

AIM: To investigate whether patients require insulin as a result of poor adherence to oral hypoglycaemic agents (OHAs) in Type 2 diabetes.
METHODS: A diabetes information system and a database of drugs dispensed for the study period 1993-1996 were used in Tayside, Scotland (population 400 000). Patients aged over 34 years with Type 2 diabetes who had at least 6 months exclusive therapy with OHAs (sulphonylureas or metformin) prior to insulin treatment were identified. Intended duration of every OHA prescription was calculated from prescription details. Adherence was estimated by dividing total intended duration of OHA therapy by study time for each patient, and compared between those who did and did not convert to insulin.
RESULTS: There were 2537 patients on sulphonylureas (51% male, mean age 67 years). There was improved adherence in the 262 patients who commenced insulin, who had mean adherence of 88.3% (95% confidence interval (CI) 85.9-90.6%) compared with the remaining 2275 patients whose mean adherence was 87.4% (95% CI 86.7-88.2%). In a logistic regression analysis, the adjusted odds ratio (OR) for commencing insulin was 1.20 (95% CI 1.07-1.35) for a quartile increase in adherence. There were 1519 patients on metformin (49% male, mean age 64 years). Mean adherence was 79.7% (95% CI 76.4-83.1%) and 83.1% (95% CI 82.0-84.1%) in 169 patients who did and 1350 who did not commence insulin, respectively, with an adjusted OR for a quartile increase in adherence of 0.91 (95% CI 0.78-1.07).
CONCLUSION: Despite suboptimal adherence to OHAs in Type 2 diabetes, this is not associated with subsequent requirement for insulin.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12147151     DOI: 10.1046/j.1464-5491.2002.00749.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  11 in total

1.  Of Struldbruggs, sugar, and gatekeepers: a tale of our times.

Authors:  David Kerr
Journal:  BMJ       Date:  2003-12-20

2.  How to use pharmacy claims data to measure patient nonadherence? The example of oral diabetics in therapy of type 2 diabetes mellitus.

Authors:  Thomas Wilke; Antje Groth; Sabrina Mueller; Dallas Reese; Roland Linder; Susanne Ahrens; Frank Verheyen
Journal:  Eur J Health Econ       Date:  2012-07-20

3.  Perceptions and experiences of taking oral hypoglycaemic agents among people of Pakistani and Indian origin: qualitative study.

Authors:  Julia Lawton; Naureen Ahmad; Nina Hallowell; Lisa Hanna; Margaret Douglas
Journal:  BMJ       Date:  2005-05-09

4.  Self-reported medication and lifestyle adherence in Hungarian patients with Type 2 diabetes.

Authors:  Balázs Hankó; Margit Kázmér; Péter Kumli; Zsuzsanna Hrágyel; Antal Samu; Zoltán Vincze; Romána Zelkó
Journal:  Pharm World Sci       Date:  2006-12-23

5.  Factors related to barriers and medication adherence in patients with type 2 diabetes mellitus: a cross-sectional study.

Authors:  Elida Zairina; Gesnita Nugraheni; Arie Sulistyarini; Catur Dian Setiawan; Sunil Kripalani; Safira Indah Lestari
Journal:  J Diabetes Metab Disord       Date:  2022-01-29

6.  Modeling the economic impact of medication adherence in type 2 diabetes: a theoretical approach.

Authors:  David S Cobden; Louis W Niessen; Frans Fh Rutten; W Ken Redekop
Journal:  Patient Prefer Adherence       Date:  2010-09-07       Impact factor: 2.711

7.  Medication oversupply in patients with diabetes.

Authors:  Carolyn T Thorpe; Heather Johnson; Anna Legreid Dopp; Joshua M Thorpe; Katie Ronk; Christine M Everett; Mari Palta; David A Mott; Betty Chewning; Loren Schleiden; Maureen A Smith
Journal:  Res Social Adm Pharm       Date:  2014-09-11

8.  Adherence to Oral Glucose-Lowering Therapies and Associations With 1-Year HbA1c: A Retrospective Cohort Analysis in a Large Primary Care Database.

Authors:  Andrew J Farmer; Lauren R Rodgers; Mike Lonergan; Beverley Shields; Michael N Weedon; Louise Donnelly; Rury R Holman; Ewan R Pearson; Andrew T Hattersley
Journal:  Diabetes Care       Date:  2015-12-17       Impact factor: 19.112

Review 9.  The significance of compliance and persistence in the treatment of diabetes, hypertension and dyslipidaemia: a review.

Authors:  J A Cramer; A Benedict; N Muszbek; A Keskinaslan; Z M Khan
Journal:  Int J Clin Pract       Date:  2007-11-05       Impact factor: 2.503

10.  The Need for a Tool to Assist Health Care Professionals and Patients in Making Medication Treatment Decisions in the Clinical Management of Type 2 Diabetes.

Authors:  Matthew Reaney
Journal:  Diabetes Spectr       Date:  2015-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.